LLIBRA OS

Owner

Goods & Services

Computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations; computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; search engine software for use in the field of pharmaceuticals, medicines and drug discovery; search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery.

Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; Providing temporary use of non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.